Contact this trialFirst, we need to learn more about you.
CAR T-cell Therapy
TEG002 for Multiple Myeloma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new treatment for multiple myeloma that uses the patient's own T cells that have been modified to express a γδTCR. The study will assess the safety and efficacy of this treatment in a small group of patients.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service